Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty-nine histologically verified cases of Paget's disease of the breast treated at the Hadassah University Hospital in the years 1949-1972 were followed up and analyzed. Dividing this material into two groups according to the presence or absence of a palpable breast tumor revealed significant difference in behavior and survival. Patients with a breast mass (34%) had a 50% axillary lymph node involvement and behaved as with any other ordinary breast cancer, with a 5-year survival rate of 40% and a 10-year survival rate of 33%. Patients with no palpable breast mass (66%) had only a 10.5% lymph node involvement, the 5-year survival rate being 94% and the 10-year survival rate being 91%. Delay in diagnosis seems to play no significant factor in survival rates and outcome. We believe radical mastectomy to be the treatment of choice in all cases of Paget's disease of the breast.
 ...
PMID:Paget's disease of the breast. 19 Apr 81

The evidence that the principles of surgical adjuvant chemotherapy developed in experimental animal systems also apply to a variety of neoplastic diseases in man has been clearly demonstrated. Micrometastatic disease can be eradicated with effective chemotherapy in several diseases. Prolongation of disease-free interval, if not cure, is now possible in diseases in which curative surgery alone or in combination with radiotherapy does not achieve these goals. The previously fatal childhood solid tumors--Wilms', Ewings' sarcoma, embryonal rhabdomyosarcoma--are curable in a high percentage of patients appropriately treated with combinations of surgery, radiotherapy, and chemotherapy. The prolongation of the disease-free interval in osteogenic sarcoma has permitted consideration of entirely new surgical approaches for this tumor in which radical amputation has traditionally been employed. The spectacular results achieved in the treatment of Stage II breast cancer may potentially save hundreds of thousands of lives in the coming decade. Clinically recognizable metastatic disease is rarely curable by any currently available treatment modality. The prolongation of disease-free intervals and production of cures when surgical adjuvant chemotherapy is employed may be partly explained by relatively more circulation, and thus drug delivery to each tumor cell, more favorable cellular kinetics, and a healthier and more immunocompetent host who is better able to withstand drug effects on normal tissues, and to participate in tumor destruction. Cures of certain patients with neoplastic diseases using surgical adjuvant chemotherapy has increased the incentive to learn more about new and old drugs and their effective use alone and in combination. Chemotherapy, in appropriate combinations with surgery, radiotherapy, and immunotherapy, may well be more efficacious in many clinical situations than the traditional use of single-modality treatment. The data presented in this paper relate solid evidence that the possibility of cure in a variety of neoplastic diseases is real.
 ...
PMID:Surgical adjuvant chemotherapy. 19 34

Chemotherapy once relegated to end stage patients has markedly improved with the use of combinations. Response rates with single agents have improved from 15 to 35%, to 50 to 70%, using combinations with an increase in complete response rates to about 25%. A series of four studies completed by the Eastern Cooperative Oncology Group over the past eight years typifies the improvement in response rates achieved by combinations as compared to single agents. Survival gain can be demonstrated for responders vs non-responders; however with current combinations, there is an apparent plateau in response rates (55 to 60%), durations of response (eight months) and survival for responders (18-22 months) as compared to survival of non-responders (six to eight months). Further improvement in response rates may occur by searching for new agents, combining hormonal and immunostimulation with chemotherapy or by sequencing non-crossresistant combinations. However, since most patients with breast cancer present with local or regional disease but go on to die of disseminated cancer, major improvements in survival are most likely to occur by treating this neoplasm as a systemic disease through cobmining effective local therapy with systemic treatments.
 ...
PMID:Chemotherapy of disseminated breast cancer. Current status and prospects. 19 80

The etiology of cancer resembles that of many other diseases in that multiple factors may be required. Because of this, the role or viruses in the etiology of human cancers is especially difficult to assess. When animal tumor systems were used as models, the roles of various predisposing characteristics in virus oncogenesis were elucidated. Extrapolation of these findings to the human diseases suggests the importance of genetics, age, hormones, immune competence, and stress in determining susceptibility to tumor development in individuals infected with an oncogenic virus. The importance of cofactors in induction of those human tumors most strongly associated with virus infection, including Burkitt's lymphoma, nasopharyngeal carcinoma, cerviccal carcinoma, acute myelogenous leukemia, and breast cancer, is reviewed. Understanding of the role of these cofactors in virus carcinogenesis may lead to disease prevention through elimination of one or more of the cofactors.
 ...
PMID:The viral etiology of cancer: a realistic approach. 19 10

A 22-year-old women developed breast cancer 15 years after radiotherapy to the lung for metastatic Wilms tumor. Her 32-year-old mother died of bilateral breast cancer, suggesting a genetic predisposition to radiogenic cancer. Recent improvements in the survival of children with certain cancers necessitate long-term surveillance for iatrogenic neoplasia, particularly when familial susceptibility is evident.
 ...
PMID:Breast carcinoma following radiotherapy of metastatic Wilm's tumor. 19 96

The aim of the study was to investigate the possibility of predicting the histologic type of different breast cancers by semi-quantitative screening of cytologic criteria. Cytologic material was obtained by the aspiration technique. The frequency of ten cytologic criteria was correlated to five histologic types of breast cancer. Hitherto, it has not been possible to define histologic types of breast carcinomas on the basis of cytologic criteria alone. While the occurrence of cellularity, intercellular cohesion, foam cells and necroses often varies from slide to slide within one particular carcinoma, other features such as nuclear diameter, polymorphism, anisonucleosis, apocrine carcinoma cells, and enlarged nucleoli are more or less uniformly distributed. The application of these cytologic criteria thus uniformly represented in a tumour may prove to be a more reliable method for classifying breast carcinomas than the use of histologic growth patterns which are often inhomogenous within each individual neoplasm.
 ...
PMID:Differential cytology of breast cancer. 19 57

Predictive tests assisting in selection of breast cancer patients for endocrine therapy have been reviewed. Information gained from histologic sections, such as degree of the tumor differentiation, degree of elastosis, Barr-body count and the DNA content, are valuable predictors of prognosis and response to endocrine therapy. The length of time between mastectomy and recurrence of metastasis is an important factor in predicting response to ablative endocrine surgery. The presence of various enzymes in the tumor tissue, blood groups, immunologic competence, altered metabolism of tryptophan, urinary excretion of steroids and in vitro hormonal responsiveness of the tumor tissue have not been widely used as predictors of tumor response to endocrine therapy. The determination of hormone receptors in primary or metastatic breast tumors is at present the most reliable test in selecting breast cancer patients for endocrine therapy. Future developments in hormone receptor assay may provide a means of tailoring endocrine therapy to the individual patient.
 ...
PMID:[Selection of patients with breast cancer with regard to endocrine therapy]. 19 40

Five stage I and stage II breast cancer patients with sinus histiocytosis in two or more enlarged regional lymph nodes were studied. Peripheral lymphocytes, serum, and nodal lymphocytes were tested in vitro for cytotoxicity against autologous normal and tumor cells. Nodal macrophages were incubated with autologous peripheral lymphocytes and these "activated" lymphocytes then were tested in vitro for cytotoxicity against autologous normal and tumor cells. Peripheral lymphocytes (L) were not cytotoxic to autologous tumor (T) cells at 25:1 L/T ratios. Nodal lymphocytes were specifically cytotoxic to autologous tumor cells. Macrophages from hyperplastic regional lymph nodes transferred tumor specific inmunity to peripheral lymphocytes. Macrophages from small, nonhyperplastic regional lymph nodes did not transfer tumor specific immunity. With the advent of adjuvant chemotherapy and its attack on systemic immunity, a quantitative, immunopathological classification of breast cancer patients is needed in order to properly select patients for further therapy.
 ...
PMID:Regional hyperplastic lymph nodes in breast cancer: the role of lymphocytes and nodal macrophages. An immunological study with a five-year follow-up. 19 57

Biochemical and immunologic studies on breast cancer with the use of cells from a human ductal cell carcinoma, BOT-2, were initiated. Antigens were extracted from the cells by mild sonication and purified by gel filtration chromatography. Only one of the three peaks from gel filtration chromatography reacted with antiserum prepared against whole BOT-2 cells. Analysis by polyacrylamide gel electrophoresis of the BOT-2 cell extract revealed many protein bands, whereas analysis of the antibody-reactive peak after gel filtration chromatography revealed fewer protein bands. Immunologic tests to identify human serum antibodies against BOT-2 cells or cell extracts were performed by fixed cell immunofluorescence, living cell membrane immunofluorescence, and indirect hemagglutination. Depending on the test, the sera from women with diagnosed, untreated mammary cancer were positive in 45--80% of the cases, whereas the sera from women without apparent breast diseases (controls) were positive in only 5--10% of the cases. The results suggested that the antigens from the BOT-2 cells will be useful in understanding the processes involved in human mammary neoplasia.
 ...
PMID:Cell-surface antigens from human breast tumor cells. 20 7

We have presented a case of adenoid cystic carcinoma of the breast and reviewed the literature, with emphasis on the behavior of this rare neoplasm and the fact that its prognosis appears to be more favorable than that of other more common histologic types of breast cancer. The accumulated information about adenoid cystic carcinoma of the breast that exists to date is insufficient to allow dogmatic statements, but one can conclude that total mastectomy seems to be the treatment of choice in selected cases.
 ...
PMID:Adenoid cystic carcinoma of the breast. 20 82


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>